A meta-analysis of 41 randomized clinical trials found that patients who received high-dose bolus tirofiban (Aggrastat, Medicure, Inc.) during PCI had a significant reduction in all-cause mortality compared with those who received eptifibatide or heparin.

Infinix Elite’s Image Quality and Versatility Enables Paris Cardiology to Bring Better Care to Multi-State Patient Population.

A pilot program from the Centers for Medicare and Medicaid Services (CMS) and the National Cardiovascular Data Registry (NCDR) that evaluated and reported risk-adjusted 30-day readmission rates after PCI may serve as a model to improve the quality and value of cardiology care.

Bakersfield Heart Hospital was as an early adopter of Abiomed’s Impella 2.5 miniature temporary ventricular assist device and now has expanded its use in elective and urgent high-risk PCI procedures.

After concerns from panels and advisory committees, the FDA approved the Watchman left atrial appendage closure device (Boston Scientific) last March. A recent reimbursement decision will likely make the Watchman available to many more people.

The Centers for Medicare & Medicaid Services (CMS) released its final national coverage determination on Feb. 8 for percutaneous left atrial appendage closure for non-valvular atrial fibrillation.

Led by strong sales of its Impella heart pump, Abiomed’s revenue for the fiscal third quarter of 2016 increased 38 percent to $85.8 million compared with the same time period in 2015.

St. Christopher's Hospital for Children in Philadelphia announced on Feb. 1 that it had had stopped conducting elective heart surgeries pending an internal review, the Philadelphia Inquirer reports.